V. Craig Jordan

26.2k total citations · 4 hit papers
349 papers, 19.4k citations indexed

About

V. Craig Jordan is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, V. Craig Jordan has authored 349 papers receiving a total of 19.4k indexed citations (citations by other indexed papers that have themselves been cited), including 303 papers in Genetics, 113 papers in Oncology and 95 papers in Molecular Biology. Recurrent topics in V. Craig Jordan's work include Estrogen and related hormone effects (297 papers), Breast Cancer Treatment Studies (50 papers) and Inflammatory mediators and NSAID effects (34 papers). V. Craig Jordan is often cited by papers focused on Estrogen and related hormone effects (297 papers), Breast Cancer Treatment Studies (50 papers) and Inflammatory mediators and NSAID effects (34 papers). V. Craig Jordan collaborates with scholars based in United States, United Kingdom and Germany. V. Craig Jordan's co-authors include Anait S. Levenson, Catherine S. Murphy, Joan S. Lewis, Philipp Y. Maximov, Leonard J. Lerner, Graham Prestwich, Marco M. Gottardis, Simon P. Robinson, Sandra Timm Pearce and Eric A. Ariazi and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

V. Craig Jordan

346 papers receiving 18.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer

1992 856 citations V. Craig Jordan et al. profile →
Tamoxifen: a most unlikely pioneering medicine

2003 597 citations V. Craig Jordan profile →
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

2001 505 citations Jane A. Cauley, Larry Norton et al. Breast Cancer Research and Treatment profile →
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY

1977 417 citations V. Craig Jordan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Craig Jordan United States	74	12.2k	6.9k	6.4k	3.4k	2.2k	349	19.4k
Benita S. Katzenellenbogen United States	102	20.3k 1.7×	14.8k 2.2×	6.5k 1.0×	2.7k 0.8×	4.4k 2.0×	359	32.5k
Donald P. McDonnell United States	88	11.5k 0.9×	11.6k 1.7×	4.3k 0.7×	3.5k 1.0×	3.0k 1.4×	272	23.8k
John A. Katzenellenbogen United States	90	15.0k 1.2×	12.0k 1.7×	5.8k 0.9×	2.7k 0.8×	3.4k 1.6×	629	33.8k
Richard J. Santen United States	78	10.2k 0.8×	6.1k 0.9×	5.2k 0.8×	2.9k 0.8×	5.2k 2.4×	355	19.6k
V. Craig Jordan United States	57	7.3k 0.6×	4.1k 0.6×	3.3k 0.5×	2.1k 0.6×	1.5k 0.7×	159	11.3k
Kathryn B. Horwitz United States	70	10.4k 0.9×	6.9k 1.0×	4.8k 0.8×	2.2k 0.6×	2.2k 1.0×	172	16.1k
Michael Reed United Kingdom	62	5.9k 0.5×	6.0k 0.9×	2.6k 0.4×	917 0.3×	2.8k 1.3×	316	14.0k
Marcello Maggiolini Italy	63	5.0k 0.4×	5.5k 0.8×	2.5k 0.4×	1.9k 0.5×	1.5k 0.7×	206	12.0k
Robert I. Nicholson United Kingdom	74	4.9k 0.4×	8.1k 1.2×	9.4k 1.5×	4.3k 1.3×	1.1k 0.5×	262	18.4k
Millard H. Lambert United States	41	3.0k 0.2×	8.6k 1.3×	2.2k 0.3×	1.3k 0.4×	1.7k 0.8×	58	13.4k

Countries citing papers authored by V. Craig Jordan

Since Specialization

Citations

This map shows the geographic impact of V. Craig Jordan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Craig Jordan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Craig Jordan more than expected).

Fields of papers citing papers by V. Craig Jordan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Craig Jordan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Craig Jordan. The network helps show where V. Craig Jordan may publish in the future.

Co-authorship network of co-authors of V. Craig Jordan

This figure shows the co-authorship network connecting the top 25 collaborators of V. Craig Jordan. A scholar is included among the top collaborators of V. Craig Jordan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Craig Jordan. V. Craig Jordan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jordan, V. Craig. (2021). Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. Breast Cancer Research and Treatment. 190(1). 19–38. 7 indexed citations

Maximov, Philipp Y., Ramona Curpăn, Sean W. Fanning, et al.. (2020). Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics. 20(1). 11–25. 9 indexed citations

Volpato, Milène, Michele Cummings, Abeer M. Shaaban, et al.. (2020). Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer. SHILAP Revista de lepidopterología. 1(5). 355–371. 6 indexed citations

Sengupta, Surojeet, et al.. (2019). Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2α) Protein. Molecular Cancer Research. 17(4). 918–928. 15 indexed citations

Obiorah, Ifeyinwa E., Ping Fan, & V. Craig Jordan. (2014). Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State. Cancer Prevention Research. 7(9). 939–949. 41 indexed citations

White, Bethany E. Perez, Rui Xiong, Hitisha Patel, et al.. (2014). Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer. Molecular Cancer Therapeutics. 13(11). 2515–2526. 16 indexed citations

Sweeney, Elizabeth E., Ping Fan, & V. Craig Jordan. (2014). Molecular Modulation of Estrogen-Induced Apoptosis by Synthetic Progestins in Hormone Replacement Therapy: An Insight into the Women's Health Initiative Study. Cancer Research. 74(23). 7060–7068. 29 indexed citations

Obiorah, Ifeyinwa E. & V. Craig Jordan. (2013). Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause The Journal of The North American Menopause Society. 20(4). 372–382. 29 indexed citations

Sweeney, Elizabeth E., Russell E. McDaniel, Philipp Y. Maximov, Ping Fan, & V. Craig Jordan. (2012). Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Hormone Molecular Biology and Clinical Investigation. 9(2). 143–163. 70 indexed citations

10.

Vogel, Victor G., Joseph P. Costantino, D. Lawrence Wickerham, et al.. (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research. 3(6). 696–706. 438 indexed citations

11.

Sengupta, Surojeet, Catherine G.N. Sharma, & V. Craig Jordan. (2010). Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Hormone Molecular Biology and Clinical Investigation. 2(2). 235–243. 67 indexed citations

12.

Ariazi, Eric A., Andrei Leitão, Tudor I. Oprea, et al.. (2007). Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Molecular Cancer Therapeutics. 6(11). 2817–2827. 52 indexed citations

13.

Nam, Jeong‐Seok, Mi‐Jin Kang, Takeshi Shimamura, et al.. (2006). Chemokine (C-C Motif) Ligand 2 Mediates the Prometastatic Effect of Dysadherin in Human Breast Cancer Cells. Cancer Research. 66(14). 7176–7184. 89 indexed citations

14.

Mishra, Sandip K., Abhijit Mazumdar, Ratna K. Vadlamudi, et al.. (2003). MICoA, a Novel Metastasis-associated Protein 1 (MTA1) Interacting Protein Coactivator, Regulates Estrogen Receptor-α Transactivation Functions. Journal of Biological Chemistry. 278(21). 19209–19219. 53 indexed citations

15.

Dardes, R. C., et al.. (2002). Regulation of Estrogen Target Genes and Growth by Selective Estrogen-Receptor Modulators in Endometrial Cancer Cells. Gynecologic Oncology. 85(3). 498–506. 42 indexed citations

16.

Cummings, Steven R., Stephen Eckert, Kathryn A. Krueger, et al.. (2000). The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial. Obstetrical & Gynecological Survey. 55(2). 100–100. 73 indexed citations

17.

Jordan, V. Craig, et al.. (1997). Tamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Clinical Oncology. 9(6). 390–394. 3 indexed citations

18.

Lindsay, Robert, David W. Dempster, & V. Craig Jordan. (1997). Estrogens and antiestrogens : basic and clinical aspects. 8 indexed citations

19.

Assikis, V J & V. Craig Jordan. (1995). Gynecologic effects of tamoxifen and the association with endometrial carcinoma. International Journal of Gynecology & Obstetrics. 49(3). 241–257. 73 indexed citations

20.

Jordan, V. Craig, Marco M. Gottardis, & P.G. Satyaswaroop. (1991). Tamoxifen‐stimulated Growth of Human Endometrial Carcinoma. Annals of the New York Academy of Sciences. 622(1). 439–446. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact